Gynecology · EndometriosisTrial Updateclinicalmid-term

Study on ICG for Enhanced Visualization of Ureters in Deep Infiltrating Endometriosis

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/22/2026, 6:01:25 AM

Assessment confidence: 65% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing clinical trial on ICG for ureter visualization in endometriosis surgery could significantly alter surgical practices and improve patient outcomes. If successful, it may reduce reliance on high-risk ureterolysis procedures, positioning the sponsoring institutions as leaders in innovative surgical techniques. Regulatory context from FDA (BsUFA II: Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act) supports the near-term read. Assessment grounded in 16 ranked evidence items (7 high-relevance).

Strategic Assessment

This could position the sponsoring institutions as leaders in innovative surgical techniques for endometriosis, influencing treatment protocols and patient outcomes. The strongest clinical anchor is A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region (ClinicalTrials.gov), sponsor/company relevance (astrazeneca). In Gynecology · Endometriosis, 1 regulatory and 2 competitive items passed relevance filtering for endometriosis treatment protocols.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. If successful, this approach may reduce the need for high-risk ureterolysis procedures, potentially changing surgical practices in endometriosis management.

Regulatory Outlook

Regulatory risk is concentrated around BsUFA II: Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act (FDA). Moderate corpus alignment. The trial's outcomes may lead to new clinical guidelines and practices that could require regulatory review and updates to existing surgical protocols involving ICG.

Key Risks

Elevated medium regulatory exposure for endometriosis treatment protocols could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Success in this trial could enhance the market positioning of the sponsoring institutions and influence treatment protocols, potentially impacting revenue streams associated with surgical interventions for endometriosis.
Upside for endometriosis treatment protocols may improve if Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) (ClinicalTrials.gov) delivers favorable follow-through.
This could position the sponsoring institutions as leaders in innovative surgical techniques for endometriosis, influencing treatment protocols and patient outcomes.

What Would Change This Assessment

This becomes more urgent if Monitor the trial's progress, particularly the feasibility results and safety data regarding ICG use in this context.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

BsUFA II: Assessment of the Program for Enhanced Review Transparency and Communication in the Biosimilar User Fee Act
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
ICG for Visualization of the Ureters in DIE
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and tolerability of linezolid as an adjunctive treatment for nontuberculous mycobacterial infections in patients with adult-onset immunodeficiency syndrome: a prospective cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

endometriosis treatment protocols

Commercial impact

medium

Success in this trial could enhance the market positioning of the sponsoring institutions and influence treatment protocols, potentially impacting revenue streams associated with surgical interventions for endometriosis.

Regulatory impact

medium

The trial's outcomes may lead to new clinical guidelines and practices that could require regulatory review and updates to existing surgical protocols involving ICG.

What to watch

Monitor the trial's progress, particularly the feasibility results and safety data regarding ICG use in this context.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.